Navigation Links
Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009
Date:5/28/2009

SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that the Chairman and CEO, James A. Joyce, will present at the 2009 RedChip Small-Cap Investor Conference and Health Information Technology Summit being held in Fort Lauderdale, Florida. Mr. Joyce's presentation is scheduled to begin at 11:30 EDT on Tuesday, June 16, 2009. The full presentation will be webcast live at www.RedChip.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

Joyce will provide an overview of Aethlon Medical and will provide an update on the company's clinical progress for its lead product, the Hemopurifier(R), a first-in-class artificial adjunct to the immune system proven to capture infectious viruses and immunosuppressive particles from the human circulatory system. Additional information can be accessed online at http://www.RedChip.com.

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic filtration devices to improve the health of individuals afflicted with infectious disease and cancer. Aethlon's lead product, the Hemopurifier(R), is a first-in-class artificial adjunct to the immune system proven to capture infectious viruses and immunosuppressive particles from the human circulatory system. The device targets to inhibit disease progression of Hepatitis-C Virus (HCV) and Human Immunodeficiency Virus (HIV), and serves as a broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats. The Hemopurifier(R) also holds promise in cancer care, as research studies verify the Hemopurifier(R) effectively captures immunosuppressive exosomes that are secreted by tumors to kill-off immune cells. At present, over sixty-five (65) Hemopurifier(R) treatments (representing approximately 260 hours of treatment time) have been conducted in multi-site studies at the Apollo Hospital, Fortis Hospital, and Sigma New-Life Hospital in India. The studies enrolled end-stage renal disease (ESRD) patients infected with either HCV or HIV. In addition to establishing treatment safety, robust viral load reductions have been reported in both HCV and HIV infected individuals.

Research studies have also demonstrated the Hemopurifier(R) is effective in capturing a broad-spectrum of viruses untreatable with drug therapy, including several of world's deadliest bioterror and pandemic threats. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF), Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), the reconstructed 1918 influenza virus (r1918), West Nile virus (WNV), and Vaccinia and Monkeypox (MPV), which both serve as models for human smallpox infection. The studies were conducted with the assistance of researchers representing: The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID); The Centers for Disease Control and Prevention (CDC); The National Institute of Virology (NIV); The Battelle Biomedical Research Center (BBRC); and The Southwest Foundation for Biomedical Research (SFBR).

Beyond therapeutic market opportunities, Aethlon is leveraging principles underlying the Hemopurifier(R) technology platform to establish a pipeline of clinical and research diagnostic products and services. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier(R) to reduce viral loads and other disease conditions, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

    Contact:

    At the Company:

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com
    or
    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com

    Investor Relations:
    RedChip Companies, Inc.
    Jon Cunningham
    (800) 733-2447, Ext. 107
    info@redchip.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2020)... ... , ... Neil Oberfeld of global law firm Greenberg Traurig, ... Trustees and committee chair of the Governance Committee for Mile High United Way, ... fights for the education, health, and financial stability of residents across Adams, Arapahoe, ...
(Date:8/31/2020)... ... August 31, 2020 , ... If you live in New York City you will always pay ... sense, it’s the law of supply and demand, but are plastic surgeons in New York ... percentage of their patients that make the four-hour trip to have expert aesthetic treatments by ...
(Date:8/28/2020)... ANGELES (PRWEB) , ... August 28, 2020 , ... ... integrative medicine and aesthetic beauty, bringing a unique perspective and approach. Armed with ... Dr. Rahi ventured out to share her knowledge of the human body with ...
Breaking Medicine Technology:
(Date:9/3/2020)... ... 03, 2020 , ... MemoryCare.com, a comprehensive resource for caregivers ... Facilities in Louisville, KY. The guide identifies 17 memory care communities based on ... Alzheimer’s Association , 5.6 million people age 65 and older are living ...
(Date:9/2/2020)... ... 02, 2020 , ... RAM Technologies, Inc., the perennial leader ... Special Needs plans, is proud to support the 2020 National Conferences on Medicare, ... supporting the event as a sponsor and exhibitor and will be showcasing their ...
(Date:9/1/2020)... , ... September 01, 2020 , ... ... has completed $3 million convertible note financing, which will be used to accelerate ... the funds from this financing, the company will continue to expand its customer ...
(Date:9/1/2020)... ... , ... As fall and winter swiftly approach and many businesses cut costs ... this time to expand and grow into a full-fledged natural health clinic over the ... be relaunching its brand new website, expanding its services menu and has recruited top-tier ...
(Date:8/31/2020)... PITTSBURGH (PRWEB) , ... August 31, 2020 , ... ... Allegheny Health Network (AHN), are joining biomedical engineers from Carnegie Mellon University (CMU) ... alternative for cardiac patients who have undergone open heart surgery. , The AGH/CMU ...
Breaking Medicine News(10 mins):